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Identity 
Other names: CDC46; MGC5315; P1-CDC46 
HGNC (Hugo): MCM5 
Location: 22q12.3 
Local order: Telomere to centromere. 
DNA/RNA 
Description 
Spanning 24,4 kb of genomic DNA, the MCM5 gene 




The unique transcript of the MCM5 gene is 2546 nt. 
The human MCM5 gene was shown to be expressed 
widely in many normal tissues, but its mRNA levels 
vary a lot. The highest levels of MCM5 mRNA 
transcripts were detected in A-431 epidermoid 
carcinoma cells, U-2 OS osteosarcoma cells, and U-251 
MG astrocytoma cells. Expression of all human genes 
of the MCM family is induced by growth stimulation 
and their mRNA levels peak at G1/S transition. The 
growth-regulated expression of MCM5 is primarily 
regulated by members of the E2F family through 





Figure 1. Schematic representation of the MCM5 gene. Exons are shown as boxes and introns as connecting lines. The coding 
sequence is highlighted as red, while 5' and 3' untranslated regions (UTRs) are shown in white. The numbers inside boxes indicate exon 
lengths and the vertical connecting lines show the intron lengths. The arrows show the position of the start codon (ATG) and stop codon 
(TGA), and the asterisk shows the position of the polyadenylation signal (AATAAA). Roman numerals indicate intron phases. The intron 
phase refers to the location of the intron within the codon; I denotes that the intron occurs after the first nucleotide of the codon, II 
denotes that the intron occurs after the second nucleotide, and 0 means that the intron occurs between distinct codons. 
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Figure 2. Amino acid sequence and structural motifs of the MCM5 protein. The asterisks (*) indicate amino acid residues being fully 
conserved in the human MCM protein family, the colons (:) indicate residues with strongly similar properties among all members of the 
human MCM family, and periods (.) indicate residues with weakly similar properties among all members of the same family. Light blue 
denotes the cis-acting ATPase elements (Walker A motif, Walker B motif and sensor 1), while yellow highlights the trans-acting ATPase 
elements (arginine finger and sensor 2). When combined in the heterohexameric MCM complex, the cis and trans motifs of adjacent 
subunits act together as an ATPase domain. Moreover, the sequence IDEFDKM (shown in dark blue color) is characteristic of most MCM 
family members. The MCM5 protein also contains a zinc finger (highlighted in pink), comprising four cysteine residues (shown in red 
color). This zinc finger is considered to play a role in the assembly of the MCM complex and its ATPase activity. 
 
Pseudogene 
Not identified so far. 
Protein 
Description 
The MCM5 protein is composed of 734 amino acid 
residues, with a calculated molecular mass of 82,3 kDa 
and a basal isoelectric point of 8,64. MCM5 is a 
member of the MCM family, a distinct subgroup of the 
AAA+ family, which consists of ATPases associated 
with various cellular activities. The MCM5 protein is 
one the six subunits composing the minichromosome 
maintenance (MCM) complex. The structural 
characteristic of MCM5 is an MCM box consisting of 
approximately 200 amino acids. This includes a Walker 
A motif containing the P-loop (phosphate-binding loop) 
of the active site and the invariant lysine residue found 
in all ATP-binding proteins, a hydrophobic Walker B 
element that is responsible for ATP hydrolysis, and 
arginine finger. The Walker B motif is part of the 
sequence IDEFDKM, which is conserved in all MCM 
proteins and defines the MCM family. 
MCM proteins form ATPase active sites at clefts 
between two subdomains: one containing a series of 
loops connecting adjacent parallel beta-strands (P-loop) 
and a second positioned C-terminal to the P-loop 
domain, called the lid. Both subdomains contain 
conserved active-site motifs: the P-loop contains motifs 
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involved in binding ATP (Walker A motif) and 
orienting the nucleophilic water molecule (Walker B 
motif and sensor 1), while the lid domain contains 
motifs that contact the gamma-phosphate of ATP 
(arginine finger and sensor 2). Therefore, ATPase 
active sites of the heterohexameric MCM complex are 
formed at dimer interfaces, with one subunit 
contributing the P-loop (cis motifs), while the adjcent 
subunit contributes the lid (trans motifs). The MCM5 
also possesses a zinc finger, located prior to the MCM 
box. This zinc finger is considered to play a role in the 
assembly of the MCM complex and its ATPase 
activity. 
Expression 
MCM5 is upregulated in the transition from the G0 to 
G1/S phase of the cell cycle. This protein is mainly 
expressed in bone marrow hematopoietic cells, 
lymphocytes in tonsil, and trophoblastic cells in 
placenta. This DNA replication licensing factor is al o 
expressed in a few other cell types, including colorectal 
glandular cells, epidermal cells of the skin and 
bronchus, urothelial cells of the urinary bladder, 
decidual cells of placenta, and glandular cells of the
pre-menopause uterus, though at lower intensity. 
Recently, it was shown that MCM5 is downregulated in 
neuroblastoma cells by miR-885-5p, which binds to the 
3'-UTR of the MCM5 mRNA. 
Localisation 
The MCM5 protein is localized to the nucleus. 
Function 
MCM5 is a member of the MCM family of chromatin-
binding proteins, implicated in the initiation of DNA 
replication. This protein can interact with at least two 
other members of this family, namely MCM2 and 
MCM3. MCM5 participates in the formation of the 
heterohexameric MCM complex, which is loaded onto 
the chromatin at origins of DNA replication with the 
aid of the multimeric CDC6-CDT1-ORC-DNA, thus 
forming together the pre-replication complex (pre-RC). 
Except for being responsible for the initiation of 
replication, the proteins composing the MCM complex 
serve as DNA helicases that unwind the DNA double 
helix at the replication forks. Moreover, MCM5 may 
actively participate in cell cycle regulation. Finally, the 
MCM complex is responsible for genome stability, as it 
limits the replication to once per cell cycle. 
MCM5, MCM3 and MCM2 constitute the peripheral 
subunits of the complex that negatively regulate th
active MCM core subunits (MCM4, MCM6 and 
MCM7). It has been proposed that MCM2 and MCM5 
form a gate in the MCM toroid. When the conformation 
is in a closed status, the dimer MCM2-MCM5 binds 
ATP; on the other hand, when the gate is open, the 
active site of the dimer is empty since no nucleotide is 
bound, and therefore no helicase activity is observed.  
 
 
Further studies suggest that the very existence of the 
gate, its topology, its conformation and the complex 
discontinuity that the MCM2/5 dimer causes, is capable 
of regulating the helicase activity of the MCM complex 
and/or is essential for the initial loading of the complex 
onto the origins of replication. 
MCM5 was shown to interact with CDC45, a key 
molecule that regulates the stages of initiation and 
elongation in the eukaryotic DNA replication. 
Interestingly, the heterodimer MCM3-MCM5 can also 
interact with the transcription factor STAT1a (STAT1 
alpha isoform), thus implying a possible role of MC5 
in transcription regulation. Increased levels of MC5 
are associated with activation of transcription. Another 
recent study showed that the MCM complex is co-
localized with RNA polymerase II (RNA Pol II) on 
chromatin of genes being constitutively transcribed, 
and that MCM5 is required for transcription elongation 
of RNA Pol II. In fact, the integrity of the MCM 
heterohexameric complex and the DNA helicase 
domain of MCM5 are essential for the process of 
transcription. Additionally, human minichromosome 
maintenance proteins including MCM5 can bind to and
interact with histones, such as H3 and H4. 
Homology 
Human MCM5 shares 96% amino acid identity and 
99% similarity with the mouse and rat Mcm5 protein. 
Moreover, it shows 35% identity and 53% similarity 
with the human MCM4 protein ("minichromosome 
maintenance complex component 4", also known as 
"CDC21 homolog"), and to quite the same extent with 
other minichromosome maintenance complex 
components, including MCM2, MCM3, MCM6, 
MCM7 isoforms 1 and 2, MCM8 isoforms 1 and 2, and 
MCM9 isoform 1. Moreover, MCM5 is structurally 
very similar to the CDC46 protein from Saccharomyces 




A mutation in a conserved residue (P -->L) enables 
MCM5 to bypass CDC7 phosphorylation, which is 
otherwise essential for the DNA replication to ensue, 
while the same mutation in other subunits of the MCM 
complex does not have any effect. It has been 
suggested that the MCM5 protein bearing this mutation 
obtains an altered conformation that allows it to 
promote the unwinding of the double helix without the 
necessity of phosphorylation of the other subunits of 
the MCM complex. Furthermore, MCM5 was shown to 
directly interact with the hypoxia-inducible factor-1 
alpha subunit (HIF1A), along with other MCM 
proteins, in order to inhibit the alterations occurring in 
gene expression by the basic helix-loop-helix 
transcription factor HIF1 under hypoxic conditions. 
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Implicated in 
Urothelial carcinoma, ovarian 
adenocarcinoma, cervical cancer 
Prognosis 
MCM5 protein overexpression was significantly 
associated with advanced histopathological stage, low 
grade of differentiation and poor prognosis in muscle-
invasive urothelial carcinoma. MCM5 protein 
expression was also found to be significantly higher in 
ovarian adenocarcinomas compared to tumors of low 
malignant potential. In ovarian adenocarcinoma, 
MCM5 upregulation was significantly associated with 
advanced tumor histopathological stage, low grade of 
differentiation, and presence of bulky residual disease, 
therefore constituting an unfavorable prognostic 
biomarker. MCM5 expression showed also a linear 
correlation with the grade of cervical dysplasia, being 
independent of HPV infection. 
Gastric adenocarcinoma, esophageal 
cancer, biliary cancer 
Prognosis 
Elevated expression of the MCM5 protein is 
significantly associated with advanced tumor size, 
presence of lymph node metastases, advanced tumor 
histopathological stage, and poor prognosis in gastric 
adenocarcinoma. Interestingly, MCM5 overexpression 
was significantly associated with lymph node positivity 
and advanced histopathological stage in diffuse-typ 
gastric adenocarcinoma, while it predicted poor 
prognosis in intestinal-type gastric adenocarcinoma. 
Furthermore, MCM5 protein expression levels in 
gastric aspirates were shown to possess high predictive 
value for esophageal cancer. MCM5 protein expression 
was also significantly higher in malignant biliary 
tissues, compared to benign ones. 
Laryngeal squamous cell carcinoma 
Prognosis 
MCM5-positive cells were present in cytological 
preparations from laryngeal squamous cell carcinoma, 
but not in those presenting atypical hyperplasia or 
inflammation in non-neoplastic tissues, supporting the
notion that liquid-based cytology enhanced by 
immunohistochemistry for MCM5 can distinguish 
between patients requiring further investigation and 
those who could be followed up without resort to 
biopsy. 
Anaplastic thyroid cancer 
Prognosis 
MCM5 overexpression was noticed in anaplastic 
thyroid cancer, in contrast with normal thyroid tissue 
and/or papillary thyroid cancer. MCM5 gene 
expression was also reported to be up-regulated at the 
mRNA level in papillary thyroid carcinoma, the  
follicular variant of papillary thyroid carcinoma, nd in 
follicular thyroid tumors, compared to hyperplastic 
nodules and follicular adenomas. However, MCM5 
mRNA expression was not associated with tumor size, 
patients' age and gender, tumor histopathological stage, 
and lymph node metastasis, in malignant thyroid 
lesions. 
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